Section Arrow
PROK.NASDAQ
- ProKidney Corp
Quotes are at least 15-min delayed:2024/05/03 20:20 EDT
Last
 2.2
+0.05 (+2.33%)
Day High 
2.37 
Prev. Close
2.15 
1-M High
3.37 
Volume 
575.06K 
Bid
2
Ask
2.38
Day Low
2.03 
Open
2.18 
1-M Low
1.4081 
Market Cap 
132.49M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.35 
20-SMA 2.14 
50-SMA 1.78 
52-W High 13.51 
52-W Low 1.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.57/-0.17
Enterprise Value
136.10M
Balance Sheet
Book Value Per Share
-17.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.318+0.0248+8.46%-- 
VAXXVaxxinity0.1411+0.0369+35.41%-- 
DNAGinkgo Bioworks Holdings0.955+0.0939+10.90%-- 
ARDXArdelyx8.72+1.93+28.42%-- 
IBRXImmunityBio9.15+0.18+2.01%-- 
Quotes are at least 15-min delayed:2024/05/03 20:20 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.